Genmab — Marts 2018
-
New study by Sponsor Oncopeptides AB: Study of Melflufen + Dex With Bortezomib or Daratumumab in Patients With RRMM (ANCHOR) NCT03481556 - https://clinicaltrials.gov/ct2/show/NCT03481556?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=03%2F28%2F2018&rank=5
-
yes, i guess that could be a logical step, was looking it up on Wiki
https://en.wikipedia.org/wiki/Melflufen lets hope it can decreasy toxicity
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind